Secondary prevention after CABG: do new agents change the paradigm?
Amélie Paquin1,2, Paul Poirier1,3, Jonathan Beaudoin1,2
1Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval.
Current Opinion in Cardiology
|October 10, 2020
Summary
Coronary artery bypass graft (CABG) surgery patients face risks of recurrent events. Novel therapies targeting inflammation, metabolism, and clotting show promise for secondary prevention after CABG.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Coronary artery bypass graft (CABG) surgery is the standard for complex coronary artery disease.
- Despite CABG success, patients experience residual risks of ischemic events and other cardiovascular outcomes.
- Secondary prevention is crucial for managing long-term outcomes post-CABG.
Purpose of the Study:
- To review recent evidence on pharmacological preventive therapies for residual cardiovascular risk in CABG patients.
- To summarize novel strategies targeting inflammatory, metabolic, and prothrombotic pathways.
- To assess the role of enhanced therapies in secondary prevention after CABG.
Main Methods:
- Literature review of recent studies on pharmacological interventions.
- Analysis of evidence for novel lipid-lowering and glucose-controlling agents.
- Evaluation of antiplatelet, anticoagulation, and other modulating therapies.
Main Results:
- Novel pharmacological strategies show promising results for secondary prevention post-CABG.
- Lipid-lowering and glucose-controlling agents demonstrate consistent benefits for native coronary artery disease and overall outcomes.
- Emerging therapies target inflammatory, metabolic, and prothrombotic pathways.
Conclusions:
- Secondary prevention is vital after CABG, with novel agents offering significant benefits.
- Further research is needed to define optimal enhanced therapies and identify new targets for graft disease.
- Long-term graft patency and multifactorial graft disease require dedicated preventive strategies.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
148
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
148
01:27Peripheral Artery Disease III: Interprofessional Care
153
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
153
01:26Coronary Artery Disease IV: Preventive Measures
501
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
501
01:28Acute Coronary Syndrome IV: Interprofessional Care
131
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
131
01:26Atherosclerosis III: Management
221
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
221
01:23Peripheral Artery Disease V: Postoperative Nursing Management
194
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
194